Mail-Order Drugs Were Supposed to Keep Costs Down. It’s Doing the Opposite.

Written By Jonathan Karush

Wall Street Journal

Jonathan Karush
Previous

Patients Not PBMs Coalition Calls on Lawmakers to Create Oversight of Pharmacy Benefit Managers
Next

3Axis Report Scrutinizes PBM Spread Pricing Practice